Table 1.
Effects of PPAR ligands on ACF formation in rats.
| Treatment (No. of mice) | ACF/colon (% inhibition) | ACs/colon (% inhibition) |
|---|---|---|
| AOM alone (12) | 83 ± 6(a) | 2.0 ± 0.24 |
| AOM + 0.01% troglitazone(8) | 68 ± 16 (18%) | 1.7 ± 0.21(15%) |
| AOM + 0.05% troglitazone(8) | 55 ± 13(b) (34%) | 1.5 ± 0.13(c) (25%) |
| AOM + 0.01% bezafibrate (8) | 75±8 (10%) | 2.0 ± 0.20 (0%) |
| AOM + 0.05% bezafibrate (8) | 53± 9(d) (36%) | 1.9 ± 0.10(5%) |
| None | 0 | 0 |
|
| ||
| 1% DSS + AOM (10) | 115 ± 22 | 2.4 ± 0.29 |
| 1% DSS + AOM + 0.01% pioglitazone (7) | 71 ± 24(e) (38%) | 1.8 ± 0.17(f) (25%) |
| 1% DSS + AOM + 0.01% troglitazone(7) | 57 ± 14(g) (50%) | 1.6 ± 0.14(g) (33%) |
| 1% DSS + AOM + 0.01% bezafibrate (7) | 59 ± 18(h) (49%) | 1.7 ± 0.16(i) (29%) |
| None | 0 | 0 |
(a)Mean ±SD.
(b–d)Significantly different from the AOM alone group: (b) P < .01; (c) P < .005; and (d) P < .001.
(e–i)Significantly different from the DSS/AOM group: (e) P < .05; (f) P < .01; (g) P < .001; (h) P < .005; and (i) P < .002.